Dimethylfumarate Impairs Neutrophil Functions.
Host defense against pathogens relies on neutrophil activation. Inadequate neutrophil activation is often associated with chronic inflammatory diseases. Neutrophils also constitute a significant portion of infiltrating cells in chronic inflammatory diseases; eg psoriasis and multiple sclerosis. Fumarates improve the latter diseases, which so far has been attributed to effects on lymphocytes and dendritic cells. Here, we focused on effects of dimethyl fumarate (DMF) on neutrophils. In vitro, DMF inhibited neutrophil activation, including changes in surface marker expression, reactive oxygen species production, formation of neutrophil extracellular traps and migration. Phagocytic ability and autoantibody-induced, neutrophil-dependent tissue injury ex vivo was also impaired by DMF. Regarding the mode of action, DMF modulates -in a stimulus-dependent manner- neutrophil activation using the PI3K/Akt-p38 MAPK- and ERK 1/2 pathways. For in vivo validation, mouse models of epidermolysis bullosa acquisita (EBA), an organ-specific autoimmune disease caused by autoantibodies to type VII collagen (COL7), were employed. In the presence of DMF, blistering induced by injection of anti-COL7 antibodies into mice was significantly impaired. DMF treatment of mice with clinically already manifested EBA led to disease improvement. Collectively, we demonstrate a profound inhibitory activity of DMF on neutrophil functions. These findings encourage wider use of DMF in patients with neutrophil-mediated diseases.Journal of Investigative Dermatology accepted article preview online, 05 October 2015. doi:10.1038/jid.2015.361.